France · Delayed Price · Currency is EUR bioMérieux Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw a 3.9% sales decline due to weak respiratory demand and geopolitical headwinds, but core reagent growth remained strong. Guidance for 2026 was revised down to 3%-5% sales growth and 0%-10% EBIT improvement, with cost controls and innovation initiatives ongoing.
Fiscal Year 2025
-
Sales grew 6.2% organically to €4 billion in 2025, with EBIT up 16% and strong cash flow. 2026 guidance targets 5–7% sales growth and at least 10% EBIT growth, despite headwinds from China and currency. Price erosion remains limited and new launches are expected to drive future growth.
-
Q3 2025 saw 3% organic sales growth, strong Spotfire and BioFire non-respiratory performance, but a late respiratory season and China softness led to revised sales guidance of 5.5-6.5% for the year. Profitability remains solid, with cost efficiencies ahead of plan.
-
H1 2025 saw 9.4% organic sales growth and a significant EBIT margin increase, driven by molecular diagnostics and industrial applications, while China’s decline weighed on microbiology and immunoassays. Free cash flow tripled, and guidance was raised for EBIT growth despite tariff and market risks.
-
Q1 2025 saw 13% organic sales growth to €1.1 billion, led by strong respiratory and industrial segments, with SPOTFIRE installations surging and robust U.S. and Japan demand. Despite tariff and China headwinds, guidance for at least 7% sales and 10% CEBIT growth in 2025 is reaffirmed.
-
A comprehensive strategic review led to the GO28 plan, targeting 7% annual sales growth and 20% operating margin by 2028. Key growth drivers include syndromic testing, point-of-care expansion, and recent acquisitions like SpinChip, with strong financial performance and market leadership maintained.
Fiscal Year 2024
-
Delivered 10.3% sales growth and 20% profitability improvement in 2024, surpassing GO28 plan targets. Free cash flow nearly tripled, with strong performance across all segments and robust outlook for 2025, including at least 7% sales growth and continued margin expansion.
-
Q3 2024 saw 11% organic sales growth to €969 million, driven by strong BioFire and SPOTFIRE performance, robust pricing, and innovation launches. Guidance for 2024 is reaffirmed, with respiratory season and FX volatility as key uncertainties.
-
H1 2024 saw 9.9% organic sales growth, strong EBIT and net income gains, and raised full-year guidance. Growth was led by BIOFIRE, SPOTFIRE, and microbiology, with robust pricing and new product launches, despite FX headwinds and some segment softness.